2
![](/content/dam/global/hcpportal/master/images/homepage/products/Trelegy/700x393.jpg)
Three patients with COPD, three daily struggles with symptoms
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. [1]
TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.
![](/content/dam/global/hcpportal/master/images/homepage/products/Trelegy/logo.png)
© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.
Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution